Tuesday, July 29, 2008

Tarenflurbil, a gamma-secretase modulator, does not seem to work in Alzheimer’s disease

Long-awaited results of a Phase III trial of tarenflurbil (Flurizan) have failed to achieve statistical significance on either of its two primary endpoints (cognition and activities of daily living). The company developing the drug, Myriad Genetics, is abandoning development of the compound for Alzheimer's disease.

Tarenflurbil had been shown in nonclinical studies to modulate gamma-secretase activity. The drug was in trials in people with mild Alzheimer's to determine if its ability to lower the amount of toxic beta-amyloid would slow or stop the course of the disease.

This was the largest and longest placebo-controlled Alzheimer disease treatment trial ever completed. The results were reported today at the Alzheimer's Association International Conference on Alzheimer's Disease being held in Chicago. Read more about the results of the study here.

No comments:

Dr. Diamandis develops network to help pathologists interface with AI computational scientists

A neuropathology colleague in Toronto (Dr. Phedias Diamandis) is developing some amazing AI-based tools for pathology and academia. He hel...